A5071951288- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- Medical Imaging Techniques and Applications
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Diagnosis and Treatment
- Breast Implant and Reconstruction
- Cancer survivorship and care
- Head and Neck Cancer Studies
- Anorectal Disease Treatments and Outcomes
- Delphi Technique in Research
- Chemotherapy-related skin toxicity
- Body Image and Dysmorphia Studies
- Hidradenitis Suppurativa and Treatments
- Endometriosis Research and Treatment
- Reproductive Biology and Fertility
- Multiple and Secondary Primary Cancers
- Tumors and Oncological Cases
- Advanced Radiotherapy Techniques
- BRCA gene mutations in cancer
- Bone health and treatments
Europa Donna
2022-2024
Athens Medical Center
2022-2024
Athens Euroclinic
2016-2021
University General Hospital Attikon
2014-2017
National and Kapodistrian University of Athens
2017
Senologic Hellenic Society
2016
Metropolitan Hospital
2015-2016
Hellenic Cooperative Oncology Group
2015
Theageneio General Hospital
2005
Alexandra Hospital
2004
Introduction Neoadjuvant systemic anticancer therapy (neoSACT) is increasingly used in the treatment of early breast cancer. Response to prognostic and allows locoregional adjuvant treatments be tailored minimise morbidity optimise oncological outcomes quality life. Accurate information about following neoSACT vital allow translation downstaging benefits into practice facilitate meaningful interpretation outcomes, particularly recurrence. Reporting studies, however, currently poor. The...
The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management not standardized. We investigated rates additional positive (LNs) at node dissection (ALND) oncologic outcomes ypN0i+ treated without ALND.
Abstract Background Circulating tumor cell (CTC) analysis is highly promising for liquid biopsy-based molecular diagnostics. We undertook a comprehensive of in vivo isolated CTCs breast cancer (BrCa). Methods In from 42 patients with early and 23 metastatic (MBC) were prospectively collected analyzed gene expression, DNA mutations, methylation before after treatment. 19 healthy donor (HD) samples as control group. identical blood draws, enumerated using CellSearch® characterized by direct IF...
Aims and Background The understanding of hormonal therapies in postmenopausal women with metastatic breast cancer has advanced greatly the past several decades. With introduction orally active, potent selective third-generation aromatase inhibitors (anastrozole, letrozole exemestane), approaches to treatment hormone-sensitive are undergoing reevaluation. For or disease that progressed on tamoxifen, all three agents active. purpose study was assess antitumor efficacy tolerance exemestane...
The host's immune system is crucially involved in cancer development and progression. ratio of regulatory to effector T-cells, as well the interplay T-cells with therapeutic agents, impact on prognosis. current study aimed comparatively investigate effect metronomic standard chemotherapy number functionality peripheral patients.CD4+CD25+ CD4+CD25- were purified from blood 36 patients co-cultured presence a polyclonal stimulus. proliferative capacity frequency CD4+CD25+/CD4+CD25- analysed...
741 Background: Gemcitabine and vinorelbine are two newer cytotoxic agents that have demonstrated promising antitumor activity favorable toxicity profiles as single-agent therapy for metastatic breast cancer. The purpose of this study was to evaluate the efficacy safety combination these in pretreated advanced Methods: A total 86 heavily patients with cancer (median age 62 years, range 35–75 years) ECOG Performance status 0–2, entered study. All had received prior adjuvant chemotherapy....
722 Background: Doxetaxel (DCT) and mitoxantrone (MX) are highly active potentially synergistic agents in the treatment of metastatic breast cancer (MBC). Letrozole, a nonsteroidal, third-generation aromatase inhibitor has shown efficacy postmenopausal women with advanced disease, producing objective tumor response rates approximately 25% after failure previous therapy. This study evaluates combination DCT MX or without letrozole patients MBC to determine toxicity this Methods: One hundred...
e22079 Background: It is still unclear whether BBC should be regarded as relapsed, metastatic or second primary tumors. Here we compared paired genotypes of with standard clinicopathological parameters. Methods: Paraffin tumors (n = 122) from 61 women BBC, synchronous 44) and metachronous 17), were histologically reviewed subtyped immunohistochemistry (IHC). In total, 116 yielded informative results MPS (58-gene panel), corresponding to 55 cases Amino acid changing (mut) variants, possible...